Daiichi Sankyo and Lilly continue talks with FDA re Prasugrel NDA « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
October 2008

M T W T F S S

« Sep Nov »

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

Daiichi Sankyo and Lilly continue talks with FDA re Prasugrel NDA

Posted on October 24, 2008 by crimsoncanary

Daiichi Sankyo and Lilly are continuing to have discussions with the FDA regarding the review of the NDA for Prasugrel

Filed under: Uncategorized | Tagged: Daiichi-Sankyo, Effent, Lilly, P2Y12, prasugrel

« Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA J&J publish series of CCR2 antagonists »